Dementia in Parkinson's disease

Hasmet A Hanagasi; Zeynep Tufekcioglu; Murat Emre

doi:10.1016/j.jns.2017.01.012

Dementia in Parkinson's disease

J Neurol Sci. 2017 Mar 15:374:26-31. doi: 10.1016/j.jns.2017.01.012. Epub 2017 Jan 5.

Authors

Hasmet A Hanagasi¹, Zeynep Tufekcioglu², Murat Emre²

Affiliations

¹ Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Istanbul, Turkey. Electronic address: hasmet@yahoo.com.
² Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Istanbul, Turkey.

PMID: 28088312
DOI: 10.1016/j.jns.2017.01.012

Abstract

Dementia can occur in a substantial number of patients with Parkinson's disease with a point prevalence close to 30%. The cognitive profile is characterized by predominant deficits in executive, visuospatial functions, attention and memory. Behavioral symptoms are frequent such as apathy, visual hallucinations and delusions. The most prominent associated pathology is Lewy body-type and biochemical deficit is cholinergic. Placebo-controlled randomized trials with cholinesterase inhibitors demonstrated modest but significant benefits in cognition, behavioral symptoms and global functions.

Keywords: Cholinesterase inhibitors; Dementia; Dementia with Lewy Bodies; Parkinson's disease.

Publication types

Review

MeSH terms

Cholinesterase Inhibitors / therapeutic use
Dementia / complications*
Dementia / drug therapy
Dementia / epidemiology
Dementia / pathology
Humans
Parkinson Disease / complications*
Parkinson Disease / epidemiology

Substances

Cholinesterase Inhibitors